Brokerages expect Imv Inc (NYSE:IMV) to report earnings per share of ($0.12) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for IMV’s earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.14). IMV posted earnings of ($0.07) per share in the same quarter last year, which indicates a negative year over year growth rate of 71.4%. The business is expected to issue its next quarterly earnings results on Thursday, August 13th.
On average, analysts expect that IMV will report full-year earnings of ($0.42) per share for the current year, with EPS estimates ranging from ($0.57) to ($0.24). For the next year, analysts expect that the firm will post earnings of ($0.44) per share, with EPS estimates ranging from ($0.59) to ($0.19). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow IMV.
IMV (NYSE:IMV) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.04 million.
NYSE IMV traded up $1.74 during trading hours on Thursday, reaching $4.74. 2,849,995 shares of the company’s stock were exchanged, compared to its average volume of 227,444. IMV has a one year low of $1.35 and a one year high of $5.12. The firm has a fifty day moving average of $2.96 and a 200-day moving average of $2.93.
Hedge funds have recently bought and sold shares of the company. 1832 Asset Management L.P. lifted its stake in shares of IMV by 172.7% in the 1st quarter. 1832 Asset Management L.P. now owns 15,000 shares of the company’s stock valued at $26,000 after purchasing an additional 9,500 shares during the period. Raymond James & Associates acquired a new position in shares of IMV in the 1st quarter valued at $42,000. JPMorgan Chase & Co. acquired a new position in shares of IMV in the 1st quarter valued at $42,000. Wells Fargo & Company MN acquired a new position in shares of IMV in the 1st quarter valued at $45,000. Finally, Royal Bank of Canada lifted its stake in shares of IMV by 14.6% in the 1st quarter. Royal Bank of Canada now owns 97,929 shares of the company’s stock valued at $171,000 after purchasing an additional 12,458 shares during the period.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Featured Story: What is the Current Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.